Humedix Co., Ltd.: debt-to-equity, ROE and more

KOSDAQ, Legal name Humedix Co., Ltd.

Latest figures are the FY2025 separate summary statements.

Latest fiscal year ratios (computed here)

Debt/equity: 8.0%
Equity ratio: 92.6%
ROE: 17.3%
Op. margin: 24.9%
Rev. growth: 5.1%
Interest coverage: n/a

Condition flags

Operating profit for 5 straight years.
Total equity is above paid-in capital. Not capital-impaired.

Interest coverage and dividends (OpenDART)

Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.

Interest coverage = operating profit ÷ interest expense

No interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.

Dividends, last 3 fiscal years

Fiscal year	Cash dividend per share	Payout ratio
2025	₩920	18.6%
2024	₩630	16.6%
2023	₩525	21.6%

Cash dividends for 3 straight years (only the 3 years OpenDART returns).

Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.

Ratios by year (computed here)

Debt-to-equity = total liabilities ÷ total equity × 100
Equity ratio = total equity ÷ total assets × 100
ROE = net income ÷ year-end total equity × 100
Operating margin = operating profit ÷ revenue × 100
Revenue growth = (this year − last year) ÷ last year × 100

Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.

Fiscal year	Debt/equity	Equity ratio	ROE	Op. margin	Rev. growth
FY2021 consolidated	52.1%	65.8%	7.1%	14.4%	n/a
FY2022 separate	63.3%	61.2%	15.2%	21.1%	11.0%
FY2023 separate	11.1%	90.0%	12.5%	24.5%	23.6%
FY2024 separate	9.3%	91.5%	17.2%	26.7%	6.3%
FY2025 separate	8.0%	92.6%	17.3%	24.9%	5.1%

Source figures (FSC summary statements)

Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.

Fiscal year	2021	2022	2023	2024	2025
Revenue	₩111.0B	₩123.2B	₩152.3B	₩161.9B	₩170.1B
Operating profit	₩16.0B	₩26.0B	₩37.3B	₩43.1B	₩42.3B
Pre-tax income	₩11.3B	₩29.0B	₩32.4B	₩48.4B	₩63.8B
Net income	₩10.1B	₩21.2B	₩24.8B	₩39.3B	₩51.8B
Total assets	₩215.9B	₩227.1B	₩220.0B	₩249.8B	₩323.6B
Total liabilities	₩73.9B	₩88.0B	₩21.9B	₩21.2B	₩24.1B
Total equity	₩142.0B	₩139.1B	₩198.1B	₩228.5B	₩299.6B
Paid-in capital	₩5.0B	₩5.0B	₩5.6B	₩5.6B	₩5.6B
Debt/equity (source value)	52.1%	63.3%	11.1%	9.3%	8.0%

Company outline (FSC)

Market: KOSDAQ
Fiscal year end: Dec
Founded: 2003-02-27
Listed: 14/12/26
Employees: 377
Auditor: 삼정회계법인
Audit opinion: 적정의견
Corporate reg. no.: 1101112727141
Outline updated: 2026-09-24

Check the original filings

Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.

Search DART for 휴메딕스

Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.